&nbsp;

Aug 2025

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Aug 2025

Regimen

ENZL

Cancer Type:

Genitourinary,

Prostate

Intent: Curative, Palliative

Funding:

Exceptional Access Program

enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), based on criteria

Exceptional Access Program

enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), based on criteria

Exceptional Access Program

enzalutamide - For the treatment metastatic castration-sensitive prostate cancer (mCSPC), based on criteria

Exceptional Access Program

enzalutamide - For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR), based on criteria

Drugs Used:

enzalutamide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

IBRUVENE

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria

Exceptional Access Program

venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria

Drugs Used:

iBRUtinib,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2025

Drug

exemestane

Other Name(s): Aromasin®

Quick Link(s):

Aug 2025

Regimen

EXEM

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

exemestane

Drugs Used:

exemestane

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

EXEM

Cancer Type:

Breast,

Gynecologic,

Endometrial

Intent: Palliative

Funding:

ODB - General Benefit

exemestane

Drugs Used:

exemestane

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

IRINTMZL

Cancer Type:

Sarcoma,

Ewing's

Intent: Palliative

Funding:

ODB - General Benefit

temozolomide

Drugs Used:

irinotecan,

temozolomide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

ENFO+PEMB

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer

New Drug Funding Program

Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin,

pembrolizumab

Quick Link(s):

Regimen Monograph

Aug 2025

Drug

enfortumab vedotin

Other Name(s): Padcev®

Quick Link(s):

Aug 2025

Regimen

IRIN+CETU; IRIN(Q2W)+CETU

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

cetuximab,

irinotecan